Rilvegostomig

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the US for the treatment of adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The approved regimen includes neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The approval follows Priority Review by the Food and Drug Administration (FDA) and is based on event-free survival (EFS) and overall survival (OS) data from the MATTERHORN Phase III trial. The EFS results were presented during the Plenary Session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The New England Journal of Medicine. OS results from MATTERHORN were presented in a Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2025. Gastric cancer is the fifth leading cause of cancer death globally, with nearly one million people diagnosed each year.1 In 2024, there were roughly 6,500 drug-treated patients in the US in early-stage and locally advanced gastric or GEJ cancer.2 Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: “This approval ushers in a new clinical paradigm for patients with early gastric and gastroesophageal junction cancers, with IMFINZI plus FLOT delivering a durable survival benefit that increases over time. As the third US approval for a perioperative IMFINZI-based regimen, this milestone further validates the perioperative approach and underscores our focus on bringing novel treatments to early-stage cancers where cure is the goal.” Yelena Y. Janjigian, MD, Chief Attending Physician of the Gastrointestinal Medical Oncology Service, Memorial Sloan Kettering Cancer Center (MSK), New York and principal investigator in the MATTERHORN trial, said: “Today’s approval marks the first immunotherapy regimen approved in the neoadjuvant setting for gastric and gastroesophageal junction cancers—with durvalumab demonstrating a clear overall survival benefit and opening an entirely new chapter in the treatment of early-stage disease. Nearly seven in 10 patients were alive at three years following treatment with the durvalumab-based perioperative regimen. This survival benefit, observed regardless of PD-L1 status, establishes a new standard of care in this curative-intent setting.” Aki Smith, Founder and Executive Director, Hope for Stomach Cancer, said: “From personal experience as a caregiver to my father, I know that for too long patients diagnosed with early gastric or gastroesophageal junction cancer have faced a high risk of their cancer returning, even after undergoing surgery and therapy intended to cure it. Today’s approval represents a major step forward in improving outcomes and offering renewed hope to those affected by this devastating disease.” In a planned interim analysis, patients treated with the IMFINZI-based perioperative regimen showed a 29% reduction in the risk of disease progression, recurrence or death versus chemotherapy alone (based on an EFS hazard ratio [HR] of 0.71; 95% confidence interval [CI] 0.58-0.86; P<0.001). Estimated median EFS was not yet reached for the IMFINZI arm versus 32.8 months for the comparator arm. An estimated 78.2% of patients treated with the IMFINZI-based perioperative regimen were event-free at one year, compared to 74.0% in the comparator arm; the estimated 24-month EFS rate was 67.4% versus 58.5%, respectively. In the final OS analysis, results showed the IMFINZI and FLOT perioperative regimen reduced the risk of death by 22% compared with chemotherapy alone (based on a HR of 0.78; 95% CI 0.63-0.96; P=0.021). An estimated 69% of patients treated with the IMFINZI-based regimen were alive at three years compared with 62% in the FLOT-only arm. With longer follow-up, the OS curves showed continued separation, signaling a greater magnitude of benefit over time for the IMFINZI-based regimen. An OS benefit was observed regardless of PD-L1 status. The safety profile for IMFINZI and FLOT chemotherapy was consistent with the known profiles of each medicine, and the percentage of patients that completed surgery was similar compared to chemotherapy alone. Grade 3 or higher adverse events due to any cause were similar between the two arms (71.6% for IMFINZI and FLOT arm; 71.2% for FLOT-only arm). The US regulatory submission was reviewed under Project Orbis, which provides a framework for concurrent submission and review of oncology medicines among participating international partners. As part of Project Orbis, the IMFINZI and FLOT perioperative regimen is also under review by regulatory authorities in Australia, Canada, and Switzerland for the same indication. Regulatory applications are also under review in the European Union (EU), Japan and several other countries. IMPORTANT SAFETY INFORMATION There are no contraindications for IMFINZI® (durvalumab). Immune-Mediated Adverse Reactions Important immune-mediated adverse reactions listed under Warnings and Precautions may not include all possible severe and fatal immune-mediated reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting treatment or after discontinuation. Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate. Withhold or permanently discontinue IMFINZI depending on severity. See USPI Dosing and Administration for specific details. In general, if IMFINZI requires interruption or discontinuation, administer systemic corticosteroid therapy (1 mg to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Immune-Mediated Pneumonitis IMFINZI can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. In patients who did not receive recent prior radiation, the incidence of immune-mediated pneumonitis was 2.4% (34/1414), including fatal (<0.1%), and Grade 3-4 (0.4%) adverse reactions. The frequency and severity of immune-mediated pneumonitis in patients who did not receive definitive chemoradiation prior to IMFINZI were similar in patients who received IMFINZI as a single agent or with ES-SCLC or BTC when given in combination with chemotherapy. Immune-Mediated Colitis IMFINZI can cause immune-mediated colitis that is frequently associated with diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (<0.1%) and Grade 3 (0.4%) adverse reactions. Immune-Mediated Hepatitis IMFINZI can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 2.8% (52/1889) of patients receiving IMFINZI, including fatal (0.2%), Grade 4 (0.3%) and Grade 3 (1.4%) adverse reactions. Immune-Mediated Endocrinopathies Adrenal Insufficiency : IMFINZI can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Immune-mediated adrenal insufficiency occurred in 0.5% (9/1889) of patients receiving IMFINZI, including Grade 3 (<0.1%) adverse reactions. Hypophysitis : IMFINZI can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts. Hypophysitis can cause hypopituitarism. Initiate symptomatic treatment including hormone replacement as clinically indicated. Grade 3 hypophysitis/hypopituitarism occurred in <0.1% (1/1889) of patients who received IMFINZI. Thyroid Disorders (Thyroiditis, Hyperthyroidism, and Hypothyroidism) : IMFINZI can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement therapy for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Thyroiditis : Immune-mediated thyroiditis occurred in 0.5% (9/1889) of patients receiving IMFINZI, including Grade 3 (<0.1%) adverse reactions. Hyperthyroidism : Immune-mediated hyperthyroidism occurred in 2.1% (39/1889) of patients receiving IMFINZI. Hypothyroidism : Immune-mediated hypothyroidism occurred in 8.3% (156/1889) of patients receiving IMFINZI, including Grade 3 (<0.1%) adverse reactions. Thyroiditis : Immune-mediated thyroiditis occurred in 0.5% (9/1889) of patients receiving IMFINZI, including Grade 3 (<0.1%) adverse reactions. Hyperthyroidism : Immune-mediated hyperthyroidism occurred in 2.1% (39/1889) of patients receiving IMFINZI. Hypothyroidism : Immune-mediated hypothyroidism occurred in 8.3% (156/1889) of patients receiving IMFINZI, including Grade 3 (<0.1%) adverse reactions. Type 1 Diabetes Mellitus, which can present with diabetic ketoacidosis : Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Grade 3 immune-mediated Type 1 diabetes mellitus occurred in <0.1% (1/1889) of patients receiving IMFINZI. Immune-Mediated Nephritis with Renal Dysfunction IMFINZI can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 0.5% (10/1889) of patients receiving IMFINZI, including Grade 3 (<0.1%) adverse reactions. Immune-Mediated Dermatology Reactions IMFINZI can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson Syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN), has occurred with PD-1/L-1 and CTLA-4 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Immune-mediated rash or dermatitis occurred in 1.8% (34/1889) of patients receiving IMFINZI, including Grade 3 (0.4%) adverse reactions. Other Immune-Mediated Adverse Reactions The following clinically significant, immune-mediated adverse reactions occurred at an incidence of less than 1% each in patients who received IMFINZI or were reported with the use of other immune-checkpoint inhibitors. Cardiac/vascular : Myocarditis, pericarditis, vasculitis. Nervous system : Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy. Ocular : Uveitis, iritis, and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment to include blindness can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss. Gastrointestinal : Pancreatitis including increases in serum amylase and lipase levels, gastritis, duodenitis. Musculoskeletal and connective tissue disorders : Myositis/polymyositis, rhabdomyolysis and associated sequelae including renal failure, arthritis, polymyalgia rheumatic. Endocrine : Hypoparathyroidism. Other (hematologic/immune) : Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenia, solid organ transplant rejection, other transplant (including corneal graft) rejection. Infusion-Related Reactions IMFINZI can cause severe or life-threatening infusion-related reactions. Monitor for signs and symptoms of infusion-related reactions. Interrupt, slow the rate of, or permanently discontinue IMFINZI based on the severity. See USPI Dosing and Administration for specific details. For Grade 1 or 2 infusion-related reactions, consider using pre-medications with subsequent doses. Infusion-related reactions occurred in 2.2% (42/1889) of patients receiving IMFINZI, including Grade 3 (0.3%) adverse reactions. Complications of Allogeneic HSCT after IMFINZI Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/L-1 blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/L-1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/L-1 blocking antibody prior to or after an allogeneic HSCT. Embryo-Fetal Toxicity Based on its mechanism of action and data from animal studies, IMFINZI can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. In females of reproductive potential, verify pregnancy status prior to initiating IMFINZI and advise them to use effective contraception during treatment with IMFINZI and for 3 months after the last dose of IMFINZI. Lactation There is no information regarding the presence of IMFINZI in human milk; however, because of the potential for serious adverse reactions in breastfed infants from IMFINZI, advise women not to breastfeed during treatment and for 3 months after the last dose. Adverse Reactions In patients with resectable GC/GEJC, the most common adverse reactions in the overall study (occurring in ≥20% of patients) were diarrhea, nausea, peripheral neuropathy, fatigue, alopecia, decreased appetite, rash, abdominal pain, vomiting, musculoskeletal pain, pyrexia, and stomatitis. In patients with resectable GC/GEJC in the neoadjuvant phase of the MATTERHORN study receiving IMFINZI in combination with FLOT chemotherapy (n=475), permanent discontinuation of IMFINZI due to an adverse reaction occurred in 2.5% of patients. Serious adverse reactions occurred in 21% of patients; the most frequent (≥2%) serious adverse reaction was diarrhea (2.5%). Deaths occurred in 1.9% of patients; deaths ≥2 patients included septic shock (0.6%) and acute coronary syndrome (0.4%). Of the 475 patients in the IMFINZI + FLOT chemotherapy treatment arm and 469 patients in the placebo + FLOT chemotherapy treatment arm who received neoadjuvant treatment, 0.6% and 0.4% of patients, respectively, did not receive surgery due to adverse reactions, and 2.3% and 2.6% of patients, respectively, had a delay in surgery due to ARs. In patients with resectable GC/GEJC in the adjuvant phase of the MATTERHORN study receiving IMFINZI in combination with FLOT chemotherapy (n=365), permanent discontinuation of IMFINZI due to an adverse reaction occurred in 7% of patients. Serious adverse reactions occurred in 29% of patients; the most frequent (≥2%) serious adverse reaction was pneumonia (2.5%). Deaths occurred in 2.2% of patients; deaths ≥2 patients included gastrointestinal perforation (0.5%) and COVID-19 (0.5%). In patients with resectable GC/GEJC in the adjuvant phase of the MATTERHORN study receiving IMFINZI alone (n=345), permanent discontinuation of IMFINZI due to an adverse reaction occurred in 6% of patients. Serious adverse reactions occurred in 14% of patients. Deaths occurred in 1.7% of patients; deaths ≥2 patients included gastrointestinal perforation (0.6%) and COVID-19 (0.6%). The safety and effectiveness of IMFINZI has not been established in pediatric patients. Indication: IMFINZI in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by single agent IMFINZI, is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). Please see additional Important Safety Information throughout and Full Prescribing Information including Medication Guide for IMFINZI. You may report side effects related to AstraZeneca products. Notes Gastric and gastroesophageal junction cancers Gastric (stomach) cancer is the fifth most common cancer worldwide and the fifth-highest leading cause of cancer mortality.1 Nearly one million new patients were diagnosed with gastric cancer in 2022, with approximately 660,000 deaths reported globally.1 In many regions, its incidence has been increasing in patients younger than 50 years old, along with other gastrointestinal (GI) malignancies.3 In 2024, there were roughly 43,000 drug-treated patients in the US, EU and Japan in early-stage and locally advanced gastric or GEJ cancer.2 Approximately 62,000 patients in these regions are expected to be newly diagnosed in this setting by 2030.4 GEJ cancer is a type of gastric cancer that arises from and spans the area where the esophagus connects to the stomach.5 Disease recurrence is common in patients with resectable gastric cancer despite undergoing surgery with curative intent and treatment with neoadjuvant/adjuvant chemotherapy.6 Approximately one in four patients with gastric cancer who undergo surgery develop recurrent disease within one year, and the five-year survival rate remains poor, with less than half of patients alive at five years.6-7 MATTERHORN MATTERHORN is a randomized, double-blind, placebo-controlled, multi-center, global Phase III trial evaluating IMFINZI as perioperative treatment for patients with resectable Stage II-IVA gastric and GEJ cancers. Perioperative therapy includes treatment before and after surgery, also known as neoadjuvant/adjuvant therapy. In the trial, 948 patients were randomized to receive a 1500mg fixed dose of IMFINZI plus FLOT chemotherapy or placebo plus FLOT chemotherapy every four weeks for two cycles prior to surgery. This was followed by IMFINZI or placebo every four weeks for up to 12 cycles after surgery (including two cycles of IMFINZI or placebo plus FLOT chemotherapy and 10 additional cycles of IMFINZI or placebo monotherapy). In the MATTERHORN trial, the primary endpoint is EFS, defined as time from randomization until the date of one of the following events (whichever occurred first): RECIST (version 1.1, per blinded independent central review assessment) progression that precludes surgery or requires non-protocol therapy during the neoadjuvant period; RECIST progression/recurrence during the adjuvant period; non-RECIST progression that precludes surgery or requires non-protocol therapy during the neoadjuvant period or discovered during surgery; progression/recurrence confirmed by biopsy post-surgery; or death due to any cause. Key secondary endpoints include pathologic complete response rate, defined as the proportion of patients who have no detectable cancer cells in resected tumor tissue following neoadjuvant therapy, and OS. The trial enrolled participants in 176 centers in 20 countries, including in the US, Canada, Europe, South America and Asia. IMFINZI IMFINZI® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor’s immune-evading tactics and releasing the inhibition of immune responses. In GI cancer, IMFINZI is approved in combination with chemotherapy in locally advanced or metastatic biliary tract cancer (BTC) and in combination with tremelimumab-actl in unresectable hepatocellular carcinoma (HCC). IMFINZI is also approved as a monotherapy in unresectable HCC in Japan and the EU. In addition to its indications in GI cancers, IMFINZI is the global standard of care based on OS in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy (CRT). Additionally, IMFINZI is approved as a perioperative treatment in combination with neoadjuvant chemotherapy in resectable NSCLC, and in combination with a short course of tremelimumab-actl and chemotherapy for the treatment of metastatic NSCLC. IMFINZI is also approved for limited-stage small cell lung cancer (SCLC) in patients whose disease has not progressed following concurrent platinum-based CRT; and in combination with chemotherapy for the treatment of extensive-stage SCLC. Perioperative IMFINZI in combination with neoadjuvant chemotherapy is approved in the US, EU, Japan and other countries for patients with muscle-invasive bladder cancer based on results from the NIAGARA Phase III trial. Additionally, in May 2025, IMFINZI added to Bacillus Calmette-Guérin induction and maintenance therapy met the primary endpoint of disease-free survival for patients with high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial. IMFINZI in combination with chemotherapy followed by IMFINZI monotherapy is approved as a 1st-line treatment for primary advanced or recurrent endometrial cancer (mismatch repair deficient disease only in the US and EU). IMFINZI in combination with chemotherapy followed by olaparib and IMFINZI is approved for patients with mismatch repair proficient advanced or recurrent endometrial cancer in the EU and Japan. Since the first approval in May 2017, more than 414,000 patients have been treated with IMFINZI. As part of a broad development program, IMFINZI is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with NSCLC, bladder cancer, breast cancer, ovarian cancer and several GI cancers. AstraZeneca in GI cancers AstraZeneca has a broad development program for the treatment of GI cancers across several medicines and a variety of tumor types and stages of disease. In 2022, GI cancers collectively represented approximately 5 million new cancer cases leading to approximately 3.3 million deaths.8 Within this program, the Company is committed to improving outcomes in gastric, liver, biliary tract, esophageal, pancreatic, and colorectal cancers. In addition to its indications in BTC and HCC, IMFINZI is being assessed in combinations, including with tremelimumab-actl, in liver, esophageal and gastric cancers in an extensive development program spanning early to late-stage disease across settings. Fam-trastuzumab deruxtecan-nxki, a HER2-directed antibody drug conjugate (ADC), is approved in the US and several other countries for HER2-positive advanced gastric cancer. Fam-trastuzumab deruxtecan-nxki is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. Olaparib, a first-in-class PARP inhibitor, is approved in the US and several other countries for the treatment of BRCA-mutated metastatic pancreatic cancer. Olaparib is developed and commercialized in collaboration with Merck & Co., Inc (MSD outside the US and Canada). The Company is also assessing rilvegostomig (AZD2936), a PD-1/TIGIT bispecific antibody, in combination with chemotherapy as an adjuvant therapy in BTC, in combination with bevacizumab with or without tremelimumab-actl as a 1st-line treatment in patients with advanced HCC, and as a 1st-line treatment in patients with HER2-negative, locally advanced unresectable or metastatic gastric and GEJ cancers. Rilvegostomig is also being evaluated in combination with Fam-trastuzumab deruxtecan-nxki in previously untreated, HER2-expressing, locally advanced or metastatic BTC. AstraZeneca is advancing multiple modalities that provide complementary mechanisms for targeting Claudin 18.2, a promising therapeutic target in gastric cancer. These include sonesitatug vedotin, a potential first-in-class ADC licensed from KYM Biosciences Inc., currently in Phase III development; AZD5863, a novel Claudin 18.2/CD3 T-cell engager bispecific antibody licensed from Harbour Biomed in Phase I development; and AZD4360, an antibody drug conjugate, currently being evaluated in a Phase I/II trial in patients with advanced solid tumors. In early development, AstraZeneca is developing C-CAR031 / AZD7003, a Glypican 3 (GPC3) armored CAR T, in HCC. C-CAR031 / AZD7003is being co-developed with AbelZeta in China where it is under evaluation in an IIT. AstraZeneca in immuno-oncology (IO) AstraZeneca is a pioneer in introducing the concept of immunotherapy into dedicated clinical areas of high unmet medical need. The Company has a comprehensive and diverse IO portfolio and pipeline anchored in immunotherapies designed to overcome evasion of the anti-tumor immune response and stimulate the body’s immune system to attack tumors. AstraZeneca strives to redefine cancer care and help transform outcomes for patients with IMFINZI as a monotherapy and in combination with tremelimumab-actl as well as other novel immunotherapies and modalities. The Company is also investigating next-generation immunotherapies like bispecific antibodies and therapeutics that harness different aspects of immunity to target cancer, including cell therapy and T-cell engagers. AstraZeneca is pursuing an innovative clinical strategy to bring IO-based therapies that deliver long-term survival to new settings across a wide range of cancer types. The Company is focused on exploring novel combination approaches to help prevent treatment resistance and drive longer immune responses. With an extensive clinical program, the Company also champions the use of IO treatment in earlier disease stages, where there is the greatest potential for cure. AstraZeneca in oncology AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death. AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow the Company on social media @AstraZeneca. References 1. 2. 3. 4. 5. 6. 7. 8. World Health Organization. World cancer fact sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf. Accessed November 2025. MSK Disclosure: Dr. Janjigian provides consulting and advisory services to AstraZeneca. US-107264 Last Updated 11/25

AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the US for the treatment of adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. 阿斯利康的Imfinzi（度伐利尤单抗）联合标准治疗FLOT化疗（氟尿嘧啶、亚叶酸、奥沙利铂和多西他赛）已在美国获批，用于治疗可切除的早期和局部晚期（II、III、IVA期）胃癌及胃食管交界处（GEJ）癌症成年患者。The approved regimen includes neoadjuvant Imfinzi in combination with chemotherapy before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy.. 批准的治疗方案包括术前使用英飞凡联合化疗作为新辅助治疗，术后使用英飞凡联合化疗作为辅助治疗，随后进行英飞凡单药治疗。The approval follows Priority Review by the Food and Drug Administration (FDA) and is based on event-free survival (EFS) and overall survival (OS) data from the MATTERHORN Phase III trial. The EFS results were presented during the Plenary Session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The New England Journal of Medicine. 该批准是在美国食品药品监督管理局（FDA）优先审查后授予的，并基于MATTERHORN III期试验中的无事件生存期（EFS）和总生存期（OS）数据。EFS结果在2025年美国临床肿瘤学会（ASCO）年会的全体会议上公布，并同步发表于《新英格兰医学杂志》。OS results from MATTERHORN were presented in a Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2025.. MATTERHORN 的 OS 结果在 2025 年欧洲医学肿瘤学会 (ESMO) 大会上的 Proffered Paper 环节中公布。Gastric cancer is the fifth leading cause of cancer death globally, with nearly one million people diagnosed each year.1 In 2024, there were roughly 6,500 drug-treated patients in the US in early-stage and locally advanced gastric or GEJ cancer.2 胃癌是全球第五大癌症死亡原因，每年有近一百万人被诊断出患有胃癌。1 在2024年，美国大约有6,500名早期和局部晚期胃癌或胃食管结合部（GEJ）癌患者接受了药物治疗。2Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: “This approval ushers in a new clinical paradigm for patients with early gastric and gastroesophageal junction cancers, with Imfinzi plus FLOT delivering a durable survival benefit that increases over time. 阿斯利康肿瘤血液学业务部执行副总裁戴夫·弗雷德里克森表示：“此次批准为早期胃癌和胃食管交界处癌患者带来了新的临床范式，Imfinzi联合FLOT能够提供随时间推移不断增加的持久生存益处。As the third US approval for a perioperative Imfinzi-based regimen, this milestone further validates the perioperative approach and underscores our focus on bringing novel treatments to early-stage cancers where cure is the goal.”. 作为第三种基于英飞凡的围手术期方案获得美国批准，这一里程碑进一步验证了围手术期方法，并强调了我们为以治愈为目标的早期癌症带来创新治疗的关注。"Yelena Y. Janjigian, MD, Chief Attending Physician of the Gastrointestinal Medical Oncology Service, Memorial Sloan Kettering Cancer Center (MSK), New York and principal investigator in the MATTERHORN trial, said: “Today’s approval marks the first immunotherapy regimen approved in the neoadjuvant setting for gastric and gastroesophageal junction cancers—with durvalumab demonstrating a clear overall survival benefit and opening an entirely new chapter in the treatment of early-stage disease. 纪念斯隆凯特琳癌症中心（MSK，纽约）胃肠道医学肿瘤科首席主治医师、MATTERHORN 试验的主要研究者叶莲娜·扬吉吉安 (Yelena Y. Janjigian) 医学博士表示：“今天的批准标志着首个免疫治疗方案在胃癌和胃食管交界处癌的新辅助治疗中获得批准——度伐利尤单抗展示了明确的总生存期益处，并开启了早期疾病治疗的全新篇章。"Nearly seven in 10 patients were alive at three years following treatment with the durvalumab-based perioperative regimen. This survival benefit, observed regardless of PD-L1 status, establishes a new standard of care in this curative-intent setting.”. 在接受基于度伐利尤单抗的围手术期治疗方案后，近七成患者在三年后仍然存活。这种生存益处与PD-L1状态无关，这在治愈意图的治疗环境中树立了新的护理标准。"Aki Smith, Founder and Executive Director, Hope for Stomach Cancer, said: “From personal experience as a caregiver to my father, I know that for too long patients diagnosed with early gastric or gastroesophageal junction cancer have faced a high risk of their cancer returning, even after undergoing surgery and therapy intended to cure it. 史密斯女士，胃癌希望的创始人兼执行董事表示：“从我个人作为父亲护理者的经验来看，我知道长期以来，被诊断为早期胃癌或胃食管结合部癌的患者即使在经历手术和治愈性治疗后，仍面临癌症复发的高风险。Today’s approval represents a major step forward in improving outcomes and offering renewed hope to those affected by this devastating disease.”. “今天的批准代表了在改善结果和为受这种毁灭性疾病影响的人们提供新的希望方面迈出了重要一步。”In a planned interim analysis, patients treated with the Imfinzi-based perioperative regimen showed a 29% reduction in the risk of disease progression, recurrence or death versus chemotherapy alone (based on an EFS hazard ratio [HR] of 0.71; 95% confidence interval [CI] 0.58-0.86; p<0.001). Estimated median EFS was not yet reached for the Imfinzi arm versus 32.8 months for the comparator arm. 在计划的中期分析中，与单独化疗相比，接受基于Imfinzi的围手术期治疗方案的患者疾病进展、复发或死亡的风险降低了29%（基于EFS风险比[HR]为0.71；95%置信区间[CI]为0.58-0.86；p<0.001）。Imfinzi组的估计中位EFS尚未达到，而对照组为32.8个月。An estimated 78.2% of patients treated with the Imfinzi-based perioperative regimen were event-free at one year, compared to 74.0% in the comparator arm; the estimated 24-month EFS rate was 67.4% versus 58.5%, respectively.. 据估计，接受基于Imfinzi的围手术期治疗方案的患者中，78.2%在一年内无事件发生，而对照组为74.0%；估计的24个月无事件生存率分别为67.4%和58.5%。In the final OS analysis, results showed the Imfinzi and FLOT perioperative regimen reduced the risk of death by 22% compared with chemotherapy alone (based on a HR of 0.78; 95% CI 0.63-0.96; p=0.021). An estimated 69% of patients treated with the Imfinzi-based regimen were alive at three years compared with 62% in the FLOT-only arm. 在最终的OS分析中，结果显示，与单独使用化疗相比，Imfinzi联合FLOT围手术期方案将死亡风险降低了22%（基于HR为0.78；95% CI 0.63-0.96；p=0.021）。据估计，使用基于Imfinzi方案治疗的患者中有69%在三年后仍然存活，而仅使用FLOT方案组为62%。With longer follow-up, the OS curves showed continued separation, signaling a greater magnitude of benefit over time for the Imfinzi-based regimen. An OS benefit was observed regardless of PD-L1 status.. 随着更长时间的随访，OS曲线显示持续分离，这表明基于Imfinzi的治疗方案随着时间的推移带来了更大的益处。无论PD-L1状态如何，都观察到了OS的获益。The safety profile for Imfinzi and FLOT chemotherapy was consistent with the known profiles of each medicine, and the percentage of patients that completed surgery was similar compared to chemotherapy alone. Grade 3 or higher adverse events due to any cause were similar between the two arms (71.6% for Imfinzi and FLOT arm; 71.2% for FLOT-only arm).. Imfinzi 和 FLOT 化疗的安全性特征与每种药物的已知特征一致，并且与单独使用化疗相比，完成手术的患者百分比相似。由于任何原因引起的 3 级或更高级别的不良事件在两组之间相似（Imfinzi 和 FLOT 组为 71.6%；仅 FLOT 组为 71.2%）。The US regulatory submission was reviewed under Project Orbis, which provides a framework for concurrent submission and review of oncology medicines among participating international partners. As part of Project Orbis, the Imfinzi and FLOT perioperative regimen is also under review by regulatory authorities in Australia, Canada, and Switzerland for the same indication. 美国的监管提交是通过Orbis项目进行审核的，该项目为参与的国际合作伙伴提供了一个同时提交和审查肿瘤药物的框架。作为Orbis项目的一部分，Imfinzi与FLOT围手术期方案也正在接受澳大利亚、加拿大和瑞士监管机构针对相同适应症的审查。Regulatory applications are also under review in the European Union (EU), Japan and several other countries.. 欧盟、日本及其他一些国家也在审查监管申请。Notes 笔记Gastric and gastroesophageal junction cancers 胃癌和胃食管结合部癌Gastric (stomach) cancer is the fifth most common cancer worldwide and the fifth-highest leading cause of cancer mortality.1 Nearly one million new patients were diagnosed with gastric cancer in 2022, with approximately 660,000 deaths reported globally.1 In many regions, its incidence has been increasing in patients younger than 50 years old, along with other gastrointestinal (GI) malignancies.3 In 2024, there were roughly 43,000 drug-treated patients in the US, EU and Japan in early-stage and locally advanced gastric or GEJ cancer.2 Approximately 62,000 patients in these regions are expected to be newly diagnosed in this setting by 2030.4. 胃癌是全球第五大常见癌症，也是癌症死亡的第五大主要原因。1 2022年有近一百万新诊断的胃癌患者，全球报告了大约660,000例死亡。1 在许多地区，50岁以下患者的发病率一直在增加，同时还有其他胃肠道（GI）恶性肿瘤。3 2024年，在美国、欧盟和日本，大约有43,000名早期和局部晚期胃癌或胃食管交界处（GEJ）癌患者接受了药物治疗。2 预计到2030年，这些地区将有约62,000名患者在此背景下被新诊断。4GEJ cancer is a type of gastric cancer that arises from and spans the area where the oesophagus connects to the stomach.5 胃食管结合部癌是一种胃癌，发生在食管与胃连接的区域。Disease recurrence is common in patients with resectable gastric cancer despite undergoing surgery with curative intent and treatment with neoadjuvant/adjuvant chemotherapy.6 Approximately one in four patients with gastric cancer who undergo surgery develop recurrent disease within one year, and the five-year survival rate remains poor, with less than half of patients alive at five years.6-7. 可切除胃癌患者即使接受根治性手术及新辅助/辅助化疗，疾病复发仍然常见。约四分之一的胃癌患者在术后一年内出现复发，五年生存率仍然较低，不足一半的患者能存活至五年。MATTERHORN 马特洪峰MATTERHORN is a randomised, double-blind, placebo-controlled, multi-centre, global Phase III trial evaluating Imfinzi as perioperative treatment for patients with resectable Stage II-IVA gastric and GEJ cancers. Perioperative therapy includes treatment before and after surgery, also known as neoadjuvant/adjuvant therapy. MATTERHORN 是一项随机、双盲、安慰剂对照、多中心的全球 III 期临床试验，评估 Imfinzi 作为可切除 II-IVA 期胃癌和胃食管结合部 (GEJ) 癌症患者的围手术期治疗。围手术期治疗包括术前和术后的治疗，也称为新辅助/辅助治疗。In the trial, 948 patients were randomised to receive a 1500mg fixed dose of Imfinzi plus FLOT chemotherapy or placebo plus FLOT chemotherapy every four weeks for two cycles prior to surgery. This was followed by Imfinzi or placebo every four weeks for up to 12 cycles after surgery (including two cycles of Imfinzi or placebo plus FLOT chemotherapy and 10 additional cycles of Imfinzi or placebo monotherapy).. 在试验中，948 名患者随机接受 1500 毫克固定剂量的 Imfinzi 加 FLOT 化疗或安慰剂加 FLOT 化疗，每四周一次，手术前进行两个周期。随后每四周接受 Imfinzi 或安慰剂，术后最多进行 12 个周期（包括两个周期的 Imfinzi 或安慰剂加 FLOT 化疗，以及 10 个额外周期的 Imfinzi 或安慰剂单药治疗）。In the MATTERHORN trial, the primary endpoint is EFS, defined as time from randomisation until the date of one of the following events (whichever occurred first): RECIST (version 1.1, per blinded independent central review assessment) progression that precludes surgery or requires non-protocol therapy during the neoadjuvant period; RECIST progression/recurrence during the adjuvant period; non-RECIST progression that precludes surgery or requires non-protocol therapy during the neoadjuvant period or discovered during surgery; progression/recurrence confirmed by biopsy post-surgery; or death due to any cause. 在 MATTERHORN 试验中，主要终点是 EFS，定义为从随机分组到以下事件（以先发生者为准）的日期之间的时间：新辅助治疗期间根据 RECIST（1.1 版，由设盲的独立中心评审评估）判定的排除手术可能或需要非方案治疗的疾病进展；辅助治疗期间的 RECIST 进展/复发；新辅助治疗期间或手术中发现的排除手术可能或需要非方案治疗的非 RECIST 进展；术后活检确认的进展/复发；或任何原因导致的死亡。Key secondary endpoints include pathologic complete response rate, defined as the proportion of patients who have no detectable cancer cells in resected tumour tissue following neoadjuvant therapy, and OS. The trial enrolled participants in 176 centres in 20 countries, including in the US, Canada, Europe, South America and Asia.. 次要终点包括病理完全缓解率，定义为在新辅助治疗后切除的肿瘤组织中未检测到癌细胞的患者比例，以及总生存期。该试验在20个国家的176个中心招募了参与者，包括美国、加拿大、欧洲、南美洲和亚洲。Imfinzi 英飞凡Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses. Imfinzi（durvalumab）是一种人源性单克隆抗体，能够与PD-L1蛋白结合，阻断PD-L1与PD-1和CD80蛋白的相互作用，从而对抗肿瘤的免疫逃逸策略并解除对免疫应答的抑制。In GI cancer, Imfinzi is approved in combination with chemotherapy in locally advanced or metastatic biliary tract cancer (BTC) and in combination with Imjudo (tremelimumab) in unresectable hepatocellular carcinoma (HCC). Imfinzi is also approved as a monotherapy in unresectable HCC in Japan and the EU.. 在胃肠道癌症中，Imfinzi联合化疗已被批准用于局部晚期或转移性胆管癌（BTC），并与Imjudo（tremelimumab）联合用于不可切除的肝细胞癌（HCC）。Imfinzi还被批准作为单一疗法用于日本和欧盟的不可切除的HCC。In addition to its indications in GI cancers, Imfinzi is the global standard of care based on OS in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy (CRT). Additionally, Imfinzi is approved as a perioperative treatment in combination with neoadjuvant chemotherapy in resectable NSCLC, and in combination with a short course of Imjudo and chemotherapy for the treatment of metastatic NSCLC. 除了在胃肠道癌症中的适应症外，Imfinzi还是基于总生存期（OS）的全球标准治疗方案，适用于在接受化放疗（CRT）后疾病未进展的不可切除III期非小细胞肺癌（NSCLC）患者的治愈意向治疗。此外，Imfinzi还被批准作为可切除NSCLC的围手术期治疗，与新辅助化疗联合使用，并且与短疗程的Imjudo和化疗联合用于治疗转移性NSCLC。Imfinzi is also approved for limited-stage small cell lung cancer (SCLC) in patients whose disease has not progressed following concurrent platinum-based CRT; and in combination with chemotherapy for the treatment of extensive-stage SCLC.. Imfinzi 还被批准用于治疗那些在接受同步铂类放化疗后疾病未进展的局限期小细胞肺癌（SCLC）患者；以及与化疗联合用于治疗广泛期小细胞肺癌（SCLC）。Perioperative Imfinzi in combination with neoadjuvant chemotherapy is approved in the US, EU, Japan and other countries for patients with muscle-invasive bladder cancer based on results from the NIAGARA Phase III trial. Additionally, in May 2025, Imfinzi added to Bacillus Calmette-Guérin induction and maintenance therapy met the primary endpoint of disease-free survival for patients with high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial.. 基于NIAGARA III期试验的结果，围手术期使用Imfinzi联合新辅助化疗已在美国、欧盟、日本及其他国家获批，用于治疗肌层浸润性膀胱癌患者。此外，在2025年5月，Imfinzi添加到卡介苗诱导和维持治疗中，在POTOMAC III期试验中达到了高危非肌层浸润性膀胱癌患者的无病生存期主要终点。Imfinzi in combination with chemotherapy followed by Imfinzi monotherapy is approved as a 1st-line treatment for primary advanced or recurrent endometrial cancer (mismatch repair deficient disease only in the US and EU). Imfinzi in combination with chemotherapy followed by Lynparza (olaparib) and Imfinzi is approved for patients with mismatch repair proficient advanced or recurrent endometrial cancer in the EU and Japan.. Imfinzi联合化疗后使用Imfinzi单药疗法已被批准作为原发性晚期或复发性子宫内膜癌（仅限美国和欧盟的错配修复缺陷患者）的一线治疗。Imfinzi联合化疗后使用Lynparza（奥拉帕尼）和Imfinzi已被批准用于欧盟和日本的错配修复完整型晚期或复发性子宫内膜癌患者。Since the first approval in May 2017, more than 414,000 patients have been treated with Imfinzi. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with NSCLC, bladder cancer, breast cancer, ovarian cancer and several GI cancers.. 自2017年5月首次获批以来，已有超过414,000名患者接受了Imfinzi治疗。作为一项广泛开发计划的一部分，Imfinzi正在作为单一疗法以及与其它抗癌疗法联合用于治疗非小细胞肺癌（NSCLC）、膀胱癌、乳腺癌、卵巢癌和多种胃肠道癌症的患者中进行测试。AstraZeneca in GI cancers 阿斯利康在胃肠道癌症领域AstraZeneca has a broad development programme for the treatment of GI cancers across several medicines and a variety of tumour types and stages of disease. In 2022, GI cancers collectively represented approximately 5 million new cancer cases leading to approximately 3.3 million deaths.8 阿斯利康拥有一个广泛的胃肠道癌症治疗开发项目，涵盖多种药物、肿瘤类型及疾病阶段。2022年，胃肠道癌症共计约有500万新发病例，导致约330万人死亡。8Within this programme, the Company is committed to improving outcomes in gastric, liver, biliary tract, oesophageal, pancreatic, and colorectal cancers. 在该计划中，公司致力于改善胃癌、肝癌、胆道癌、食道癌、胰腺癌和结直肠癌的治疗效果。In addition to its indications in BTC and HCC, Imfinzi is being assessed in combinations, including with Imjudo, in liver, oesophageal and gastric cancers in an extensive development programme spanning early to late-stage disease across settings. 除了在BTC和HCC中的适应症外，Imfinzi正在一项广泛的开发计划中进行评估，包括与Imjudo联合应用于肝癌、食管癌和胃癌，覆盖从早期到晚期的疾病阶段。Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), is approved in the US and several other countries for HER2-positive advanced gastric cancer. Enhertu is jointly developed and commercialised by AstraZeneca and Daiichi Sankyo. Enhertu（trastuzumab deruxtecan）是一种HER2导向的抗体药物偶联物（ADC），已在美国和其他一些国家获批用于HER2阳性晚期胃癌。Enhertu由阿斯利康和第一三共共同开发和商业化。Lynparza, a first-in-class PARP inhibitor, is approved in the US and several other countries for the treatment of BRCA-mutated metastatic pancreatic cancer. Lynparza is developed and commercialised in collaboration with MSD (Merck & Co., Inc. inside the US and Canada). Lynparza，作为一流的PARP抑制剂，已在美国和其他几个国家获批用于治疗BRCA突变的转移性胰腺癌。Lynparza由MSD（美国和加拿大境内的默克公司）合作开发并商业化。The Company is also assessing rilvegostomig (AZD2936), a PD-1/TIGIT bispecific antibody, in combination with chemotherapy as an adjuvant therapy in BTC, in combination with bevacizumab with or without Imjudo as a 1st-line treatment in patients with advanced HCC, and as a 1st-line treatment in patients with HER2-negative, locally advanced unresectable or metastatic gastric and GEJ cancers. 公司还在评估rilvegostomig（AZD2936），一种PD-1/TIGIT双特异性抗体，与化疗联合作为BTC的辅助治疗，与贝伐单抗联合使用、无论是否联合Imjudo作为晚期HCC患者的一线治疗，以及作为HER2阴性、局部晚期不可切除或转移性胃癌和胃食管交界处癌症患者的一线治疗。Rilvegostomig is also being evaluated in combination with Enhertu in previously untreated, HER2-expressing, locally advanced or metastatic BTC.. Rilvegostomig 也正在与 Enhertu 联合评估，用于既往未经治疗、HER2 表达的局部晚期或转移性 BTC。AstraZeneca is advancing multiple modalities that provide complementary mechanisms for targeting Claudin 18.2, a promising therapeutic target in gastric cancer. These include sonesitatug vedotin, a potential first-in-class ADC licensed from KYM Biosciences Inc., currently in Phase III development; AZD5863, a novel Claudin 18.2/CD3 T-cell engager bispecific antibody licensed from Harbour Biomed in Phase I development; and AZD4360, an antibody drug conjugate, currently being evaluated in a Phase I/II trial in patients with advanced solid tumours.. 阿斯利康正在推进多种针对Claudin 18.2的互补作用机制，Claudin 18.2是胃癌中一个颇具前景的治疗靶点。这些机制包括从KYM生物科学公司授权的潜在first-in-class抗体药物偶联物（ADC）sonesitatug vedotin，目前处于III期开发阶段；从 Harbour BioMed 授权的新型Claudin 18.2/CD3 T细胞结合双特异性抗体AZD5863，目前处于I期开发阶段；以及抗体药物偶联物AZD4360，目前正在晚期实体瘤患者中进行I/II期试验评估。In early development, AstraZeneca is developing C-CAR031 / AZD7003, a Glypican 3 (GPC3) armoured CAR T, in HCC. C-CAR031 / AZD7003is being co-developed with AbelZeta in China where it is under evaluation in an IIT. 在早期开发中，阿斯利康正在肝细胞癌（HCC）领域开发C-CAR031 / AZD7003，一种Glypican 3（GPC3）装甲CAR-T。C-CAR031 / AZD7003正与中国AbelZeta共同开发，并在当地一项研究者发起的试验（IIT）中进行评估。AstraZeneca in immuno-oncology (IO) 阿斯利康在免疫肿瘤学（IO）领域AstraZeneca is a pioneer in introducing the concept of immunotherapy into dedicated clinical areas of high unmet medical need. The Company has a comprehensive and diverse IO portfolio and pipeline anchored in immunotherapies designed to overcome evasion of the anti-tumour immune response and stimulate the body’s immune system to attack tumours.. 阿斯利康是将免疫治疗概念引入高度未满足医疗需求的专用临床领域的先驱。公司拥有全面且多样化的IO产品组合与管线，专注于设计克服肿瘤免疫逃逸并刺激人体免疫系统攻击肿瘤的免疫疗法。AstraZeneca strives to redefine cancer care and help transform outcomes for patients with Imfinzi as a monotherapy and in combination with Imjudo as well as other novel immunotherapies and modalities. The Company is also investigating next-generation immunotherapies like bispecific antibodies and therapeutics that harness different aspects of immunity to target cancer, including cell therapy and T-cell engagers.. 阿斯利康致力于通过英飞凡单药治疗以及与英达珠联合使用，重新定义癌症护理并帮助改善患者的治疗效果，同时还探索其他新型免疫疗法和治疗模式。公司还在研究下一代免疫疗法，例如双特异性抗体和利用免疫不同方面的治疗方法，包括细胞疗法和T细胞接合器等，以靶向癌症。AstraZeneca is pursuing an innovative clinical strategy to bring IO-based therapies that deliver long-term survival to new settings across a wide range of cancer types. The Company is focused on exploring novel combination approaches to help prevent treatment resistance and drive longer immune responses. 阿斯利康正在追求一种创新的临床策略，将基于IO的疗法引入到各种癌症类型的新治疗场景中，以实现长期生存。公司专注于探索新型组合方法，以帮助防止治疗耐药性并推动更持久的免疫反应。With an extensive clinical programme, the Company also champions the use of IO treatment in earlier disease stages, where there is the greatest potential for cure.. 通过广泛的临床项目，公司还倡导在疾病早期阶段使用IO治疗，因为这是治愈潜力最大的时期。AstraZeneca in oncology 阿斯利康在肿瘤学领域AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. 阿斯利康正引领一场肿瘤学革命，致力于为各种形式的癌症提供治愈方案。通过科学研究深入了解癌症及其所有复杂性，发现、开发并交付改变生命的药物给患者。The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience. 公司的重点是一些最具挑战性的癌症。正是通过持续的创新，阿斯利康建立了业内最多样化的产品组合和研发管线之一，有潜力推动医学实践的变革，并改善患者的体验。AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death. 阿斯利康有重新定义癌症护理并有朝一日消除癌症作为死亡原因的愿景。AstraZeneca 阿斯利康AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. 阿斯利康（LSE/STO/Nasdaq：AZN）是一家全球领先的、以科学为导向的生物制药公司，专注于肿瘤学、罕见病以及包括心血管、肾脏与代谢、呼吸与免疫学在内的生物制药领域的处方药的研发、生产和商业化。Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.. 总部位于英国剑桥的阿斯利康公司的创新药物销往125多个国家，并被全球数百万患者使用。请访问astrazeneca.com并关注该公司社交媒体@AstraZeneca。Contacts 联系人For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. 如需了解如何联系投资者关系团队的详细信息，请点击这里。如需联系媒体，请点击这里。References 参考文献Source:astrazeneca.com 来源：astrazeneca.com